153 related articles for article (PubMed ID: 8139377)
1. Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
Ritzi EM; Pyo S
Life Sci; 1994; 54(13):887-99. PubMed ID: 8139377
[TBL] [Abstract][Full Text] [Related]
2. Levels of viral glycoprotein provide a dose-dependent measure of tumor cell inhibition.
Ritzi EM; Pyo S
Life Sci; 1989; 44(26):2041-50. PubMed ID: 2545986
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect reflected by plasma levels of a viral protein during combination chemotherapeutic treatment of mammary tumor-bearing mice.
Ritzi EM; Martin DS; Stolfi RL; Spiegelman S
Cancer Res; 1985 Nov; 45(11 Pt 1):5374-8. PubMed ID: 3840411
[TBL] [Abstract][Full Text] [Related]
4. Quantitative flow cytometry of mouse mammary tumor virus envelope glycoprotein (gp52): alternative measures of hormone-mediated change in a viral cell surface antigen.
Ritzi EM
J Virol Methods; 1992 Oct; 40(1):11-30. PubMed ID: 1331158
[TBL] [Abstract][Full Text] [Related]
5. Estimation of mouse mammary tumor virus gp52 abundance by protein A assay: a comparison of viral antigen expression on C3H and GR mammary tumor cells.
Callis AH; Ritzi EM
Intervirology; 1981; 15(2):111-20. PubMed ID: 6271704
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of a viral protein during adjuvant treatment: reflection of murine mammary tumor status and therapeutic effect.
Ritzi EM; Martin DS; Stolfi RL
Cancer Res; 1986 Jun; 46(6):2804-9. PubMed ID: 3754489
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoids stimulate the release of a viral tumor marker (MMTV gp52) while inhibiting tumor cell growth.
Ritzi EM; Walthall EB
J Steroid Biochem; 1989 Apr; 32(4):499-505. PubMed ID: 2542692
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of viral antigens released into plasma and culture fluids by murine mammary tumor cells.
Ritzi EM; Smith BA; Stolfi RL; Martin DS
Cancer Res; 1981 Oct; 41(10):3885-90. PubMed ID: 6269731
[TBL] [Abstract][Full Text] [Related]
9. Positive and negative modification of dexamethasone-mediated MMTV gp52 release by progesterone pretreatment of tumor cells.
Ritzi EM; Walthall EB
Intervirology; 1989; 30(2):111-6. PubMed ID: 2542181
[TBL] [Abstract][Full Text] [Related]
10. Shedding of virus-free MMTV gp52 by nonproducer mammary tumor cells: a source of tumor marker in the presence and absence of dexamethasone.
Ritzi EM; Walthall EB
Intervirology; 1989; 30(2):102-10. PubMed ID: 2542180
[TBL] [Abstract][Full Text] [Related]
11. Lipids alter the level and distribution of mouse mammary tumor virus gp52 in vitro.
Sunzeri FJ; Buehring GC
Cancer Lett; 1993 Oct; 74(1-2):57-64. PubMed ID: 8287372
[TBL] [Abstract][Full Text] [Related]
12. Elevation of mouse mammary tumor virus envelope glycoprotein (Gp52) by growth factors.
Ritzi EM; Walthall EB
Intervirology; 1988; 29(3):144-53. PubMed ID: 2846465
[TBL] [Abstract][Full Text] [Related]
13. Mice with spontaneous mammary tumors develop type-specific neutralizing and cytotoxic antibodies against the mouse mammary tumor virus envelope protein gp52.
Schochetman G; Arthur LO; Long CW; Massey RJ
J Virol; 1979 Oct; 32(1):131-9. PubMed ID: 94356
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
15. Quantitative flow cytometry reveals a hierarchy of glucocorticoid effect on cell surface mouse mammary tumor virus gp52.
Ritzi EM
J Steroid Biochem Mol Biol; 1996 Jan; 57(1-2):33-42. PubMed ID: 8645615
[TBL] [Abstract][Full Text] [Related]
16. Second messengers induced by the envelope protein of a retrovirus.
Bolander FF
Mol Cell Endocrinol; 1997 Apr; 129(1):27-32. PubMed ID: 9175626
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a C3Hf mammary tumor cell line expressing endogenous mouse mammary tumor virus: antigenic and genetic relationships of this virus with highly oncogenic mouse mammary tumor viruses.
Arthur LO; Lovinger GG; Schochetman G
J Virol; 1979 Dec; 32(3):852-9. PubMed ID: 92576
[TBL] [Abstract][Full Text] [Related]
20. Detection and characterization of mouse mammary tumor virus cell surface antigens: estimation of antigen abundance by protein A assay.
Callis AH; Ritzi EM
J Virol; 1980 Sep; 35(3):876-87. PubMed ID: 6252344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
